Discovery Partner – AI & Biomedical Talent (Contract) at Abata Therapeutics

Seattle, Washington, United States

Apply Now

Not SpecifiedCompensation

Senior (5 to 8 years)Experience Level

Full TimeJob Type

UnknownVisa

Biotechnology, Artificial IntelligenceIndustries

Requirements

8+ years of recruiting experience, with a focus on AI, ML, engineering, or biomedical science roles
Proven success recruiting AI scientists, engineers, and interdisciplinary researchers
Familiarity with the AI and biomedical research ecosystem, including major conferences, publishing venues, and academic-to-industry talent flows
Familiarity with talent pipelines from GitHub, open-source projects, and leading academic/industry labs
Strong communication and relationship-building skills with technical talent and internal leaders
Data-driven approach with experience using metrics to optimize performance
Passion for generative AI, biomedical innovation, and shaping the future of human health

Responsibilities

Manage full-cycle recruitment for roles spanning AI/ML research, research engineering, software engineering, and biomedical AI
Develop sourcing strategies that reach into AI research labs, open-source communities, engineering networks, and biomedical science hubs
Partner with hiring managers to define competencies and create compelling job profiles
Represent the company as a talent ambassador at AI/ML and biomedical events
Guide interviewers and teams to run a structured, fair, and rigorous evaluation process
Use recruiting data and analytics to refine search strategies and improve hiring outcomes

Skills

full-cycle recruiting

sourcing strategies

AI/ML recruiting

biomedical recruiting

talent acquisition

hiring analytics

structured interviews

technical recruiting

Abata Therapeutics

Develops therapies for autoimmune diseases

About Abata Therapeutics

Abata Therapeutics develops therapies for autoimmune diseases, focusing on type 1 diabetes. Their main product, ABA 201, is a Treg cell therapy aimed at patients with some remaining beta cell function. This therapy works by utilizing regulatory T cells to improve patient outcomes. Unlike many competitors, Abata targets a specific niche within the autoimmune disease market and collaborates with partners like ElevateBio for process development and manufacturing. The company's goal is to transform treatment options for autoimmune diseases through advanced research and development.

Cambridge, MassachusettsHeadquarters

2021Year Founded

$184.8MTotal Funding

EARLY_VCCompany Stage

BiotechnologyIndustries

11-50Employees

Risks

Intensifying competition from companies like Sangamo Therapeutics may impact Abata's market share.

Stringent FDA scrutiny on manufacturing could delay Abata's clinical trials.

Rising clinical trial costs pose financial risks to Abata's pipeline progression.

Differentiation

Abata focuses on Treg cell therapies for autoimmune diseases like MS and diabetes.

Their lead product, ABA 201, targets type 1 diabetes with remaining beta cell function.

Abata's strategic partnership with ElevateBio enhances their manufacturing capabilities.

Upsides

Recent investment from Bristol Myers Squibb boosts Abata's Treg therapy pipeline development.

FDA's accelerated approval pathways may expedite Abata's clinical trials.

Growing autoimmune disease prevalence increases demand for Abata's innovative treatments.

Land your dream remote job 3x faster with AI

Try Jobo Free